33 Result(s)

Article

Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains

Hematologic response criteria in light chain (AL) amyloidosis require the difference in involved and uninvolved free light chains (dFLC) to be at least 5 mg/dl. We describe the clinical presentation and outcom...

S Sidana, N Tandon, A Dispenzieri, M A Gertz, F K Buadi, M Q Lacy, D Dingli… in Leukemia (2018)

Article

Pomalidomide–dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial

Despite therapeutic advances, multiple myeloma remains incurable, with limited options for patients with refractory disease. We conducted a large, multi-cohort clinical trial testing various doses and treatmen...

S Ailawadhi, J R Mikhael, B R LaPlant, K M Laumann, S Kumar, V Roy, D Dingli… in Leukemia (2018)

Article

Natural history of t(11;14) multiple myeloma

Translocation (11;14) on interphase fluorescent in situ hybridization in plasma cells is regarded as a standard risk prognostic marker in multiple myeloma based on studies conducted before introduction of current...

A Lakshman, M Alhaj Moustafa, S V Rajkumar, A Dispenzieri, M A Gertz, F K Buadi… in Leukemia (2018)

Article

Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category

The significance of interphase fluorescence in situ hybridization (iFISH) by regimen type was assessed in 692 immunoglobulin light-chain (AL) amyloidosis patients with iFISH at diagnosis. First-line treatment was...

E Muchtar, A Dispenzieri, S K Kumar, R P Ketterling, D Dingli, M Q Lacy… in Leukemia (2017)

Article

Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression

The presence of high numbers of circulating clonal plasma cells (cPCs) in patients with smoldering multiple myeloma (SMM), detected by a slide-based immunofluorescence assay, has been associated with a shorter...

W I Gonsalves, S V Rajkumar, A Dispenzieri, D Dingli, M M Timm, W G Morice… in Leukemia (2017)

Article

Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival

Immunoparesis is an adverse prognostic marker in plasma cell proliferative disorders. Its impact in AL amyloidosis has not been explored in depth. Newly diagnosed AL amyloidosis patients (n=998) were evaluated fo...

E Muchtar, A Dispenzieri, S K Kumar, F K Buadi, M Q Lacy, S Zeldenrust… in Leukemia (2017)

Article

Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents

Outcomes for patients with multiple myeloma (MM) have improved in recent years owing to use of novel agents and high-dose therapy followed by autologous stem cell transplant (ASCT). We analyzed the outcomes of...

N Majithia, S V Rajkumar, M Q Lacy, F K Buadi, A Dispenzieri, M A Gertz… in Leukemia (2016)

Article

Clinical course and outcomes of patients with multiple myeloma who relapse after autologous stem cell therapy

W I Gonsalves, S V Rajkumar, M A Gertz, A Dispenzieri… in Bone Marrow Transplantation (2016)

Article

Risk factors for and outcomes of patients with POEMS syndrome who experience progression after first-line treatment

Although clinical improvement is almost universal with therapy in patients with POEMS (an acronym for polyneuropathy, organomegaly, endocrinopathies, monoclonal protein and a variety of skin changes) syndrome,...

T V Kourelis, F K Buadi, M A Gertz, M Q Lacy, S K Kumar, P Kapoor, R S Go… in Leukemia (2016)

Article

Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma

Early high-dose therapy (HDT), consisting of high-dose melphalan and autologous stem cell transplantation following doublet or triplet novel agent induction, is a preferred management strategy for transplant-e...

G P Kaufman, M A Gertz, A Dispenzieri, M Q Lacy, F K Buadi, D Dingli… in Leukemia (2016)

Article

Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy

Normalization of the serum-free light-chain ratio (FLCr) with the absence of bone marrow monoclonal plasma cells following achievement of a complete response (CR) to therapy denotes a stringent CR in multiple ...

M Alhaj Moustafa, S V Rajkumar, A Dispenzieri, M A Gertz, M Q Lacy, F K Buadi… in Leukemia (2015)

Article

Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma

We studied 351 patients with smoldering multiple myeloma (SMM) in whom the underlying primary molecular cytogenetic subtype could be determined based on cytoplasmic immunoglobulin fluorescent in situ hybridizatio...

S V Rajkumar, V Gupta, R Fonseca, A Dispenzieri, W I Gonsalves, D Larson… in Leukemia (2013)

Article

A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma

Patients with asymptomatic (smoldering) multiple myeloma (AMM) have a high risk of transformation to active multiple myeloma (MM). Bisphosphonates such as zoledronic acid (ZLD) reduce skeletal events in MM and...

T E Witzig, K M Laumann, M Q Lacy, S R Hayman, A Dispenzieri, S Kumar… in Leukemia (2013)